LensAI Bio-Native Suite
Transform workflow—intelligence to adapt at every stage
HYFT Base™ - Data and Insights Foundation
- Full data integration for single-query access across sequence, structure, and function
- Explore using the power of billions of pre-indexed HYFT patterns to uncover biological connections between targets, mechanisms, and therapeutic relevance
- Start with the Company's framework—or add data—to instantly access deep biological context, with or without custom inputs
- Continuously enrich and adapt insights as data evolves
HYFT Matrix™ - Exploration Layer
- Uncover hidden candidates that share critical patterns with top performers
- Prioritize true diversity by scoring across mechanisms, epitopes, formats, and biological context
- Filter faster with biological intelligence to reduce downstream experimentation and refine focus
- Advance with confidence through transparent scoring that shows what matters and why
HYFT Prime™ - Engineering and Design Engine
- Multi-dimensional optimization — immunogenicity, affinity, and developability in one integrated loop
- Refine and select using multi-dimensional biological evidence, not isolated properties
- Advance molecules engineered for performance, scalability, and clinical translation
- Generate de novo candidates through LensAI reasoning over HYFT molecular fingerprints
From Sequence to Full Biological Context—at Scale
Start with a single sequence and scale across the service-based discovery continuum.
LensAI connects data to structural and functional evidence to deliver a traceable, 360° biological view that supports decision-making across workflows.
Grab Sources And More Company Details Here: HYFT Website. -----
Institutional Interest in the Space: What BlackRock, Vanguard, and State Street Are Watching
Antibody discovery and biologics AI platforms are attracting serious institutional capital — not just from specialist biotech funds, but from the largest asset managers in the world.
OmniAb, Inc. (NASDAQ: OABI) — a comparable biologics discovery platform company — counts BlackRock, Inc., Vanguard Group, and State Street Corp. among its largest institutional shareholders, with 135 institutional owners collectively holding over 53Mn shares in the company.
That kind of institutional presence in a niche biologics discovery name isn't accidental.
These firms run exhaustive due diligence before establishing meaningful positions, and their presence signals a broader conviction that AI-native biologics discovery platforms represent durable, scalable value.
HYFT operates in the same sector, with a technology argument that is arguably more differentiated — the functional layer approach is distinct from what OmniAb or most other platforms in this space are doing. -----
And as we mentioned earlier in the report, (Nasdaq: HYFT) has multiple potential catalysts on our radar. Check them out:
#1. HYFT Potential Catalyst - A New Systematic Report Identifies 20+ Discovery-Originated Drug Candidates (10 Of These Programs Are In Active Clinical Trials).
The Biology Came First.
Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today.
AUSTIN, Texas, May 18, 2026--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is wholly owned, advanced, and funded by the partner. MindWalk’s contribution was the molecule itself — the immunization strategy, the discovery campaign, the lead identification, and the candidate selection that made clinical entry possible. In select cases that contribution extended into early development. The same wet-lab and AI capabilities that produced these programs are available to MindWalk’s partners today and are the foundation of the Company’s own proprietary portfolio. The full report, available Here, identifies each partner by program.
The significance of this record extends beyond the clinical count. The more than 400 peer-reviewed publications and patents produced through this work establish a scientific standard that is rare in this industry: a discovery capability that has consistently produced partner-owned clinical-stage assets across therapeutic areas and modalities. That standard is the measure against which MindWalk holds every subsequent capability, including B cell Llama™ camelid nanobody discovery and the HYFT® biological intelligence infrastructure. The HYFT® system and LensAI™ platform were developed independently as a purpose-built AI architecture — not derived from the wet-lab programs, but subsequently integrated with them, and now embedded in every internal MindWalk program. The Knowledge Graph that underpins HYFT® — 660Mn biological patterns, 25Bn relationships, refined over 20 years of curation — is not a general-purpose AI substrate trained on public data. It is a function-aware representation of biological sequence space, built on biological pattern recognition derived from the breadth of the global biosphere, and now operating in direct integration with the wet-lab discovery workflows that produced these programs.
"Before AI was a hypothesis in life sciences, our scientists were generating the molecules that are now in clinical trials at our partners. That history is not a credential we display — it is a standard we hold ourselves to. When we bring a new capability into this organization, the question is always the same: can it meet the bar that wet-lab discovery set? HYFT® and LensAI™ were built by world-class scientists pursuing a singular focus: creating the most rigorous biological representation system ever developed. We integrated them because they cleared that bar. The result is a discovery organization where the biology and the AI interrogate each other — and where neither would be as good without the other." — Dr. Jennifer Bath, PhD, Chief Executive Officer and President, MindWalk Holdings Corp.
...
Read the full article here. -----
#2. HYFT Potential Catalyst - The Company Announced Its 3rd Consecutive Quarter Of YoY Revenue Growth (52% Increase In Q3 2026 From Q3 2025).
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform
AUSTIN, Texas, March 12, 2026--(BUSINESS WIRE)--MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. ...
Revenue for Q3 was $4.2Mn, a 52 percent increase from $2.7Mn in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year revenue growth. US revenue doubled year over year to $2.6Mn. The Company's largest enterprise AI client signed a one-year LensAI platform contract, the first contracted, recurring platform revenue agreement in the Company's history, shifting a part of MindWalk's revenue from project-based to contracted and recurring.
"This quarter, MindWalk reported its third consecutive year-over-year revenue increase and advanced three pipeline programs toward data readouts. US revenue doubled year over year, reflecting our deliberate, strategic focus on North America, including the establishment of biologics services operations in the Boston and Cambridge area and ongoing commercial investment in that market. Recently, our largest enterprise AI client signed a one-year LensAI platform contract, the first of its kind for us. LensAI is actively being rolled out across our broader client base, and this is a contract structure we are scaling."
— Dr. Jennifer Bath, CEO & President, MindWalk Holdings Corp.
...
Read the full article here. -----
#3. HYFT Potential Catalyst - An Average Of 5 Analyst Targets Suggest Significant Potential Upside (Triple-Digit).
Check out what MarketBeat is reporting: |
